Home / Partnerships


background Revivo logo circuls.png__PID:a6249f01-094e-45ba-b11d-4c8a1151715c

Partner with us

We collaborate with businesses and institutions to develop advanced in vitro models using our proprietary technology and scientific expertise. Our assistance is tailored to your needs, and ranges from providing you with platforms and technical support, to the development and validation of customised models. Contact us to know more.

Some of our partners 

keel univrsirty.png__PID:440ad913-f0c1-48c2-b259-03d52448ec5d
university of ferrara .png__PID:5187bf7f-e3e4-42d6-88ba-b0e36b905be3
shefield university logo.jpg__PID:87078b4e-7dec-43bf-939f-ec64f704440a

Case study #1: University of Ferrara

Status: ongoing

We are collaborating to develop complex in vitro models of the central nervous system including both the blood-brain barrier and the blood-cerebrospinal fluid barrier.


Eugenol induced dopamine release from neuron-like PC12 cells after its permeation across the physiological brain barriers simulated in a new organ-on-a-chip platform

Pavan et. al., 2023

This study explores Eugenol's neuropharmacological properties using the CELLBLOKS® organ-on-a-chip platform, allowing the simulation of multiple physiological barriers within one system. The models include human cerebral microvascular endothelial cells (hCMEC/D3) representing the BBB, Human Retinal Pigment Epithelial (HRPE) cells as a BCSFB model, and Rat small Intestinal Epithelial cells (IEC-6) mimicking the GI barrier. The research examines Eugenol's ability to induce dopamine release in neuron-like PC12 cells grown in NANOSTACKSTM inserts.The findings extend beyond neuropharmacology, offering insights into Eugenol's interactions with these barriers. This research may have broader therapeutic implications, with the potential to impact various strategies. Presented at the 73rd SIF National Congress, this study marks a significant step in understanding Eugenol's pharmacology and its passage through physiological barriers


Case study #2: University of Sheffield

Status: ongoing

This collaboration focuses on the development of in vitro models of head and neck cancer, to improve our understanding of the tumour microenvironment.

Application Note

Development of Accurate 3D Models of Head and Neck Cancer Using Revivocell's NANOSTACKSTM Platform

Khurram et al.,2023; School of Clinical Dentistry at The University of Sheffield, United Kingdom

In the proof of concept study conducted by Prof. Ali Khurram and his team from the School of Clinical Dentistry at The University of Sheffield, United Kingdom, they utilized cancer cells from the primary site of head and neck cancer, cancer cells from the metastasis site from the same patient, and normal fibroblasts. By incorporating these cell types into Revivocell's NANOSTACKSTM platform, the researchers aimed to develop accurate 3D models that mimic the tumor microenvironment and enable a better understanding of head and neck cancer progression and metastasis. This preliminary work, published by Prof. Ali Khurram et al., highlights the potential of Revivocell's technology for advanced cancer research and sets the stage for further investigations into therapeutic interventions.


Need some help?

If you're interested in discovering how  our organ models can benefit your research, we invite you to get in touch with us. Our team is available to provide further insights and address any inquiries you may have.

Contact information


Daresbury Laboratory, Sci-Tech Daresbury, Keckwick Lane Daresbury, Cheshire, WA4 4AD




BioLabs@NYU LANGONE, 180 Varick St, Floor 6, New York, NY 10014


Revivocell Brands

NANOSTACKS stip white.png__PID:23bff30e-eca7-4125-9868-6ac89c7cf352
CellBloks_logo.ai registered trademark. white png.png__PID:71578730-e4eb-4f50-852a-7c721b84f60e